The Caris Registry’s Molecular Data To Help Predict Responses To Cancer Therapy
IRVING, Texas– February 16, 2010 – Caris Life Sciences (Caris®) – a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology – today announced the launch of The Caris Registry℠, a biomarker-driven repository to help predict clinical benefit and patients’ responses to cancer therapy including chemotherapy, immunotherapy and biological therapy.
“The Caris Registry provides a centralized, real-time data repository through which treating physicians can share and expand their understanding of personalized treatment options for their patients,” said Alan Wright, Senior Vice President of Strategy at Caris. “...

